secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celcuity Inc. (CELC)
CIK:        0001603454
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0001493152-24-022227
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celcuity prices $60M common stock offering of 3.871M shares at $15.50
---------------------------------------------------------------------

- 3,871,000 shares priced at $15.50 per share; gross proceeds $60.0M, net ~$56.2M.
- Proceeds to fund working capital, R&D, and Phase 3 trial of gedatolisib for HR+/HER2- advanced breast cancer.
- Investors include BVF Partners, Vivo Capital, Eventide Asset Management, Samlyn Capital, Driehaus Capital, Blue Owl Healthcare.
- Offering closed May 31, 2024; existing cash plus proceeds expected to fund operations through at least H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603454/000149315224022227/0001493152-24-022227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603454/000149315224022227/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-022227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer